Most Read Articles
5 days ago
Less focus must be given on pretreatment blood pressure (BP) levels, which rarely predict future untreated BP levels or rule out capacity to benefit from BP lowering in high cardiovascular risk patients, according to recent study. Focus must be directed instead on prompt, empirical treatment to maintain lower BP for individuals with high BP or high risk.
16 Nov 2018
Atrial fibrillation appears to be the strongest determinant of stroke over 48 years of follow-up in males, a study has found.
15 Nov 2018
Psychological functioning consistently predicts symptom severity and health-related quality of life (hr-QOL) in atrial fibrillation (AF) patients with preserved left ventricular function, a recent study has found.
Audrey Abella, 16 Nov 2018
Supplementation with either omega-3 fatty acids (ie, fish oil) or vitamin D did not reduce the incidence of major cardiovascular (CV) events (ie, composite of myocardial infarction [MI], stroke, and CV death) or total invasive cancer, according to the VITAL* trial presented at AHA 2018.

Ectopic fat accumulation in prepubertal females predicts cardiometabolic risk in adulthood

27 May 2018
The obesity epidemic hits Malaysia hard with cardiovascular disease occurring during younger ages.

In prepubertal females, high adiposity in the abdominal region and ectopic fat accumulation in the skeletal muscle increase cardiometabolic risk in adulthood, a recent study has found. On the other hand, skeletal muscle size and muscle mass are not important cardiometabolic risk factors.

The muscle cross-sectional area and lean mass of the leg was significantly and positively associated with the metabolic syndrome score. A similar trend was observed for muscle cross-sectional area and lean mass for the whole body and for android fat mass. Overall, p-values ranged from <0.05–0.001.

In contrast, muscle density (r2=0.012; p<0.05) and the skeletal muscle index (r2=0.201; p<0.001) were significantly and inversely associated with metabolic syndrome score. The significance of these relationships was attenuated after adjusting for android or whole-body fat mass.

“To our knowledge, this is the first study to examine the longitudinal associations between adiposity, skeletal muscle size, mass and density and cardio-metabolic risk from childhood to early adulthood,” said researchers.

“[T]his report suggests that skeletal muscle size and mass per se are not associated with cardio-metabolic risk factors during pubertal growth,” they added, noting that waist circumference or waist-to-height ratio, instead, could be valuable in evaluating cardiometabolic risk in children.

For the study, researchers recruited 236 prepubertal females (mean age 11.2 years) and followed them for an average of 7.5 years. Dual-energy X-ray absorptiometry was used to measure fat mass and whole-body lean mass, while peripheral quantitative computerized tomography was used to assess muscle cross-sectional area and skeletal muscle fat content (represented as muscle density) of the lower leg.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
Less focus must be given on pretreatment blood pressure (BP) levels, which rarely predict future untreated BP levels or rule out capacity to benefit from BP lowering in high cardiovascular risk patients, according to recent study. Focus must be directed instead on prompt, empirical treatment to maintain lower BP for individuals with high BP or high risk.
16 Nov 2018
Atrial fibrillation appears to be the strongest determinant of stroke over 48 years of follow-up in males, a study has found.
15 Nov 2018
Psychological functioning consistently predicts symptom severity and health-related quality of life (hr-QOL) in atrial fibrillation (AF) patients with preserved left ventricular function, a recent study has found.
Audrey Abella, 16 Nov 2018
Supplementation with either omega-3 fatty acids (ie, fish oil) or vitamin D did not reduce the incidence of major cardiovascular (CV) events (ie, composite of myocardial infarction [MI], stroke, and CV death) or total invasive cancer, according to the VITAL* trial presented at AHA 2018.